NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Investment research Market and company reports Stock market data Share Exchange ...

Shares in Novo Nordisk were up nearly 12% today – hiking ... today could also reflect a bounceback from a fall-off in the stock's value last week, after the revelation that Wegovy, Ozempic ...

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometabolic diseases.

During the third quarter, the Lazard International Equity Advantage Portfolio underperformed the MSCI EAFE Index (net of fees ...

Nvidia slipped in early morning trading after Chinese quantitative trading fund Goku submitted a new AI research paper. Investors can stay up-to-date with all of the latest stock market news at ...